II. Indications
-
Hypertension
- Not first-line Antihypertensives, and avoid using as monotherapy (higher risk of CVA and CHF)
-
Benign Prostatic Hypertrophy
- Selective Alpha-1a Antagonists (e.g. Tamsulosin) are preferred
-
Medical Expulsive Therapy for Ureteral Stone
- Replaced by the preferred Selective Alpha-1a Antagonists (e.g. Tamsulosin)
III. Dosing
-
Hypertension
- Start: 1 mg orally at bedtime and titrate dose (Maximum 16 mg/day)
-
Benign Prostatic Hypertrophy (replaced by Selective Alpha-1a Antagonists)
- Start: 1 mg orally at bedtime and titrate every 1-2 weeks doubling dose, to a maximum of 8 mg at bedtime
- Extended release formulation (e.g. Cardura XL) 4 mg in am daily (may increase to 8 mg daily after 3-4 weeks)
-
Medical Expulsive Therapy for Ureteral Stone (replaced by Selective Alpha-1a Antagonists)
- Extended release formulation (e.g. Cardura XL) 4 mg orally daily (not FDA approved)
IV. Safety
- Unknown safety in Pregnancy
- Unknown safety in Lactation
V. Mechanism
- See Alpha Adrenergic Receptor (Alpha-1 Antagonist)
-
Peripheral Alpha-1 Adrenergic Antagonist
- Arterial and Venous Vasodilation
VI. Adverse Effects
VII. Drug Interactions
- Strong CYP3A4 Inhibitors (e.g. Clarithromycin, Itraconazole)
- Risk of increased Doxazosin effects (e.g. Orthostatic Hypotension)
VIII. Resources
IX. References
- (2020) Med Lett Drugs Ther 62(1598): 73-80
- Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 62-3
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
Images: Related links to external sites (from Bing)
Related Studies
doxazosin (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
DOXAZOSIN MESYLATE 1 MG TAB | Generic | $0.09 each |
DOXAZOSIN MESYLATE 2 MG TAB | Generic | $0.07 each |
DOXAZOSIN MESYLATE 4 MG TAB | Generic | $0.09 each |
DOXAZOSIN MESYLATE 8 MG TAB | Generic | $0.11 each |
Ontology: Doxazosin (C0114873)
Definition (MSH) | A prazosin-related compound that is a selective alpha-1-adrenergic blocker. |
Definition (NCI) | A quinazoline with antihypertensive and antineoplastic properties. Doxazosin is an alpha-adrenergic antagonist that selectively inhibits alpha-1 adrenergic receptors. Blockages of the alpha-1 adrenergic action on the vascular smooth muscles lead to a decrease in vascular resistance and antihypertensive activity. This agent also shows high affinity to alpha-1c adrenoceptor, the predominant functional type in the prostate, which may partially attribute to its effect in treatment of benign prostatic hyperplasia. Furthermore, doxazosin induces apoptosis in prostate cancer cells mediated through inhibition of protein kinase B (PKB)/Akt-signaling death receptor regulatory pathway. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D017292 |
SnomedCT | 108556006, 372508002 |
LNC | LP171393-4 |
English | Doxazosin, Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)-, Doxazosin [Chemical/Ingredient], doxazosin (medication), alpha blockers doxazosin, doxazosin, DOXAZOSIN, Doxazosin (product), Doxazosin (substance) |
Swedish | Doxazosin |
Czech | doxazosin |
Finnish | Doksatsosiini |
Russian | DOKSAZOZIN, ДОКСАЗОЗИН |
Japanese | ドキサゾシン, ドキサゾシンメシレート, メシル酸ドキサゾシン |
Spanish | Doxazosina, Doxazosin, doxazosina (producto), doxazosina (sustancia), doxazosina |
Portuguese | Doxazossina, Doxazosin, Doxazosina |
Polish | Doksazosyna, Metylosulfonian doksazosyny |
French | Doxazosine |
German | Doxazosin |
Italian | Dossazosina |
Ontology: Cardura (C0678136)
Definition (MSH) | Trade name in United States. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D017292 |
English | Carduran, cardura, carduran, Cardura, Cardular, Pfizer Brand of Doxazosin Mesylate, Zoxan |